Anti noxa sc 2697

IFNγ- treated and control cells were subjected to immunofluorescence staining as described [31 (link)]. Primary antibodies, anti-Noxa (SC-2697), 1:200; anti-Tom20 (Sc-11415), 1:200; anti-Bap31 (Sc-18579), 1:200 (each Santa Cruz Biotechnology Inc., CA, USA) were incubated treated and control cells for 2 h at room temperature. After three successive washing with PBS, the cells were incubated with Alexa Flour labelled secondary antibodies for 2 h at room temperature protected from light. To remove nonspecific binding of the secondary antibodies, the cells were washed three times with PBS, and subsequently mounted using DAKO mounting medium. Photomicrographs were taken on a fluorescence microscope (Leica, Wetzlar, Germany).

BLM cells were allowed to grow for 24 hrs before the exposure to imiquimod for 24 hrs. Then the cells were subjected to immunofluorescence staining as described 20. Primary antibodies, anti‐Noxa (SC‐2697), 1:200; anti‐Tom20 (Sc‐11415), 1:200; anti‐Bap31 (Sc‐17764), 1:200 (each Santa Cruz Biotechnology Inc.) were allowed to bind for 2 hrs at room temperature. Subsequently, the cells were washed three times in PBS and incubated with Alexa Flour‐labelled secondary antibodies for 2 hrs at room temperature. After an additional three washes in PBS, the cells were mounted using DAKO mounting medium. Photomicrographs were taken on a Leica fluorescence microscope (Leica, Wetzlar, Germany).